Clinical characteristics and outcomes of severe COVID-19 patients treated with lopinavir–ritonavir (LPV/r) within 12 days of onset of symptoms
| Case No. | Sex | Age | Category of oxygen support | Comorbidity | Symptom onset to LPV/r therapy (days) | Course of LPV/r use (days) | Clinical outcomes | Hospitalisation time (days) |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 63 | Non-invasive ventilation | None | 9 | 12 | Discharge | 44 |
| 2 | M | 32 | High-flow oxygen | Hepatitis B infection | 9 | 7 | Discharge | 17 |
| 3 | M | 71 | Non-invasive ventilation | None | 11 | 8 | Death | N/A |
| 4 | M | 73 | High-flow oxygen | Rheumatoid arthritis | 4 | 10 | Discharge | 15 |
| 5 | M | 55 | High-flow oxygen | Hypertension Haemorrhage | 7 | 12 | Discharge | 42 |
| 6 | M | 67 | High-flow oxygen | None | 6 | 10 | Discharge | 13 |
| 7 | M | 57 | High-flow oxygen | None | 10 | 7 | Discharge | 45 |
| 8 | M | 77 | High-flow oxygen | Gout | 12 | 12 | Discharge | 29 |
| 9 | F | 75 | High-flow oxygen | None | 8 | 14 | Discharge | 22 |
| 10 | F | 57 | Non-invasive ventilation | Hypertension, diabetes | 11 | 11 | Discharge | 39 |
| 11 | M | 46 | High-flow oxygen | Hypertension | 12 | 10 | Discharge | 11 |
| 12 | F | 65 | High-flow oxygen | None | 3 | 12 | Discharge | 17 |
| 13 | M | 33 | High-flow oxygen | None | 11 | 15 | Discharge | 15 |
| 14 | F | 46 | High-flow oxygen | None | 5 | 14 | Discharge | 17 |
| 15 | M | 61 | High-flow oxygen | Diabetes | 11 | 9 | Discharge | 14 |
| 16 | F | 38 | High-flow oxygen | None | 2 | 11 | Discharge | 13 |
| 17 | F | 57 | High-flow oxygen | None | 5 | 17 | Discharge | 35 |
| 18 | F | 72 | High-flow oxygen | None | 12 | 10 | Discharge | 27 |
| 19 | M | 42 | High-flow oxygen | Diabetes | 9 | 12 | Discharge | 17 |